Cannabis/Cannabinoids for Treating COVID-19 Associated Neuropsychiatric Complications
Abstract Graphical abstract: Research shows that currently there is no clinical evidence to support the use of cannabis or any of its compounds including CBD for treating any of the neuropsychiatric complications of COVID-19. Thus, it is important that the addiction physicians/psychiatrists caution their patients from using cannabis or cannabis products for treating any such complications. Article type: Research Article Keywords: COVID-19, Cannabis, Cannabidiol, CBD, Neuropsychiatric Authors: Jag H. Khalsa, Sanjay B. Maggirwar, Greg Bunt Affiliations: grid.420090.f0000 0004 0533 7147Medical
This article is available to registered members
Create a free account to access our full library of peer-reviewed research on medical cannabis.
Join — it's freeAlready a member? Log in